In a week after the stop of vaccination by Oxford/AstraZeneca medicine, the authorities of South Africa asked the Serum Institute of India to take back a million dose of vaccine supplied at the beginning of February as The Economic Times reported.
It is specified that such a decision is tied with the fact that the clinical trials of the vaccine in South Africa showed that it provides insufficient protect from mild or moderate Covid-19 caused by a mutated variant of the coronavirus. This batch of vaccine arrived in South Africa a few days ago.
Currently, the authorities of the country hold vaccination of the people from the risk groups, particularly, medics, by Johnson&Johnson vaccine.
As we reported, the Oxford-AstraZeneca vaccine is less effective against the South African mutated variant, early data from a small study showed that.
A small trial of just 2,026 people in South Africa found the jab had 'limited efficacy' in protecting against mild and moderate disease caused by the mutant strain, which has been found in 11 people in the UK who have not recently travelled from abroad.